Page last updated: 2024-11-02

pd 98059 and Erythremia

pd 98059 has been researched along with Erythremia in 2 studies

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.

Research Excerpts

ExcerptRelevanceReference
"R115777 is an orally bioavailable farnesyltransferase inhibitor (FTI) that has displayed encouraging activity in patients with acute myeloid leukemia."1.32In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. ( Gray, LA; Kaufmann, SH; Mesa, RA; Reeder, T; Schroeder, G; Tefferi, A, 2003)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Laubach, JP1
Fu, P1
Jiang, X1
Salter, KH1
Potti, A1
Arcasoy, MO1
Mesa, RA1
Tefferi, A1
Gray, LA1
Reeder, T1
Schroeder, G1
Kaufmann, SH1

Other Studies

2 other studies available for pd 98059 and Erythremia

ArticleYear
Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
    Experimental hematology, 2009, Volume: 37, Issue:12

    Topics: Antigens, CD34; Apoptosis; Cell Proliferation; Cells, Cultured; Culture Media, Serum-Free; Dose-Resp

2009
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
    Leukemia, 2003, Volume: 17, Issue:5

    Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protei

2003